Business context and reporting period
Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company developing T-cell therapies, including EB103 (CD19-targeted) and EB104 (CD19/CD22-targeted). It has no approved products and has generated no product revenue. This 10-Q reports the unaudited three months ended September 30, 2023—Estrella’s fiscal 2024 first quarter, rather than calendar 2023 Q1 as stated in the request.
The September 29, 2023 business combination with TradeUP Acquisition Corp. was accounted for as a reverse recapitalization, with Estrella as the accounting acquirer. The combined company’s shares trade as ESLA and warrants as ESLAW.
Financial performance and condition
| Metric | Quarter ended Sep. 30, 2023 | Comparable 2022 quarter |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $0.48 million | $2.61 million |
| General and administrative expense | $1.39 million | $0.28 million |
| Total operating expense / net loss | $1.87 million | $2.89 million |
| Net loss per share, basic and diluted | $1.78 | $34.33 |
| Operating cash flow | $(0.28) million | $(1.10) million |
At September 30, cash was $22.14 million, including $5.07 million held in trust for shareholder redemptions and offset by a $5.07 million redemption payable. Total assets were $27.35 million, current liabilities $17.28 million, and stockholders’ equity $10.07 million. Related-party accounts payable were $9.34 million. The company reported a $14.06 million accumulated deficit.
Investing cash outflow was $0.11 million. Financing cash inflow was $20.05 million, including $10.0 million PIPE proceeds, $9.02 million net proceeds from Series A preferred-stock issuance, a $0.30 million promissory note, and $0.73 million from the recapitalization. Cash increased by $19.66 million during the quarter. Debt was limited to the $0.30 million unsecured note, bearing 12% interest; it was repaid October 27, 2023. Profit margins are not meaningful given the absence of revenue.
Material changes versus the prior comparable period
- Net loss narrowed by approximately $1.01 million. R&D expense fell by about $2.12 million, primarily because no Services Agreement service fees with Eureka were incurred in the quarter.
- G&A expense rose by about $1.11 million, reflecting higher professional fees, accelerated stock-based compensation upon the business combination, and approximately $0.40 million of executive bonuses. Stock-based compensation totaled $1.19 million versus $0.10 million a year earlier.
- The business combination and concurrent financings materially increased cash and equity; common shares outstanding rose to 35.20 million at September 30.
Outlook, risks and unusual items
- The FDA cleared the EB103 IND in March 2023. Management expects the Phase I/II Starlight-1 trial to begin in the first half of 2024. The company expects expenses and operating losses to increase as it advances development and incurs public-company costs; revenue is not expected for at least the next few years.
- Management stated that available funds and the credit line were expected to cover working capital and debt obligations for at least 12 months from the financial-statement issuance date. This outlook depends on assumptions and may change; management anticipates needing additional capital, which may not be available on acceptable terms.
- After quarter-end, the company paid approximately $9.3 million to Eureka under its License and Services Agreements, approximately $5.1 million to settle the redemption payable, and the $0.3 million note. The September 30 cash balance therefore predates these payments.
- A potential White Lion equity line of up to $50 million is conditional: its required registration statement was not effective, and shareholder approval may be needed for issuances reaching 20% or more of outstanding shares. Warrant exercise proceeds are uncertain; the $11.50 exercise price was well above the $1.20 November 15 closing share price.
- Eureka is a key development-services and manufacturing provider. The filing describes reliance on Eureka and the risk that replacement services could be unavailable or more costly. License terms include development milestones and single-digit royalties on future net sales.
- Disclosure controls were deemed ineffective due to material weaknesses involving accounting expertise and staffing, written policies and control procedures, and review evidence. Management outlined hiring, training, external internal-control support, and governance improvements.
- The filing reports no material legal proceedings or material changes to previously disclosed risk factors. It identifies inflation and geopolitical conflicts as possible adverse factors but says their specific impact is not readily determinable.
Important facts for investors to verify
- Post-quarter cash and liquidity after the Eureka, redemption, and note payments, and the resulting expected cash runway.
- Timing and costs of the Starlight-1 trial and progress on EB103/EB104 development.
- Whether the White Lion equity-line registration becomes effective and whether any required shareholder approval is obtained.
- Remediation of the disclosed material weaknesses and effectiveness of financial-reporting controls in subsequent filings.
- Related-party obligations, future Eureka service and manufacturing arrangements, and potential milestone or royalty payments.
- Potential PIPE investor share issuances, including the stated contingent share provisions, and dilution from equity-line usage, warrants, or other securities.